1. Wheelock EF. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science. 1965; 149:310–311.
2. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957; 147:258–267.
3. Billiau A, Matthys P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev. 2009; 20:97–113.
4. McKenzie AN, Spits H, Eberl G. Innate lymphoid cells in inflammation and immunity. Immunity. 2014; 41:366–374.
5. Mackaness GB. The influence of immunologically committed lymphoid cells on macrophage activity
in vivo
. J Exp Med. 1969; 129:973–992.
6. Douvas GS, Looker DL, Vatter AE, Crowle AJ. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun. 1985; 50:1–8.
7. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983; 158:670–689.
8. Hoffmann HH, Schneider WM, Rice CM. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol. 2015; 36:124–138.
9. Lazear HM, Nice TJ, Diamond MS. Interferon-lambda: immune functions at barrier surfaces and beyond. Immunity. 2015; 43:15–28.
10. García-Sastre A. Ten strategies of interferon evasion by viruses. Cell Host Microbe. 2017; 22:176–184.
11. Diamond MS, Harris E. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology. 2001; 289:297–311.
12. Wack A, Terczyńska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol. 2015; 16:802–809.
13. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004; 75:163–189.
14. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001; 19:65–91.
15. Kropp KA, Robertson KA, Sing G, Rodriguez-Martin S, Blanc M, Lacaze P, Hassim MF, Khondoker MR, Busche A, Dickinson P, et al. Reversible inhibition of murine cytomegalovirus replication by gamma interferon (IFN-γ) in primary macrophages involves a primed type I IFN-signaling subnetwork for full establishment of an immediate-early antiviral state. J Virol. 2011; 85:10286–10299.
16. Sun B, Skjæveland I, Svingerud T, Zou J, Jørgensen J, Robertsen B. Antiviral activity of salmonid gamma interferon against infectious pancreatic necrosis virus and salmonid alphavirus and its dependency on type I interferon. J Virol. 2011; 85:9188–9198.
17. Hwang S, Maloney NS, Bruinsma MW, Goel G, Duan E, Zhang L, Shrestha B, Diamond MS, Dani A, Sosnovtsev SV, et al. Nondegradative role of Atg5-Atg12/Atg16L1 autophagy protein complex in antiviral activity of interferon gamma. Cell Host Microbe. 2012; 11:397–409.
18. Prestwood TR, Morar MM, Zellweger RM, Miller R, May MM, Yauch LE, Lada SM, Shresta S. Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice. J Virol. 2012; 86:12561–12570.
19. Wieland SF, Vega RG, Müller R, Evans CF, Hilbush B, Guidotti LG, Sutcliffe JG, Schultz PG, Chisari FV. Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol. 2003; 77:1227–1236.
20. Weizman OE, Adams NM, Schuster IS, Krishna C, Pritykin Y, Lau C, Degli-Esposti MA, Leslie CS, Sun JC, O'Sullivan TE. Ilc1 confer early host protection at initial sites of viral infection. Cell. 2017; 171:795–808.e12.
21. Lu B, Ebensperger C, Dembic Z, Wang Y, Kvatyuk M, Lu T, Coffman RL, Pestka S, Rothman PB. Targeted disruption of the interferon-gamma receptor 2 gene results in severe immune defects in mice. Proc Natl Acad Sci U S A. 1998; 95:8233–8238.
22. Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science. 1994; 264:1918–1921.
23. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, Vilcek J, Zinkernagel RM, Aguet M. Immune response in mice that lack the interferon-gamma receptor. Science. 1993; 259:1742–1745.
24. Changotra H, Jia Y, Moore TN, Liu G, Kahan SM, Sosnovtsev SV, Karst SM. Type I and type II interferons inhibit the translation of murine norovirus proteins. J Virol. 2009; 83:5683–5692.
25. Senik A, Stefanos S, Kolb JP, Lucero M, Falcoff E. Enhancement of mouse natural killer cell activity by type II interferon. Ann Immunol (Paris). 1980; 131C:349–361.
26. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983; 158:670–689.
27. Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol. 2000; 165:3571–3577.
28. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol. 1988; 140:4245–4252.
29. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4
+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6:1123–1132.
30. Leibson HJ, Gefter M, Zlotnik A, Marrack P, Kappler JW. Role of gamma-interferon in antibody-producing responses. Nature. 1984; 309:799–801.
31. Sidman CL, Marshall JD, Shultz LD, Gray PW, Johnson HM. Gamma-interferon is one of several direct B cell-maturing lymphokines. Nature. 1984; 309:801–804.
32. He XS, Draghi M, Mahmood K, Holmes TH, Kemble GW, Dekker CL, Arvin AM, Parham P, Greenberg HB. T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J Clin Invest. 2004; 114:1812–1819.
33. Hurgin V, Novick D, Werman A, Dinarello CA, Rubinstein M. Antiviral and immunoregulatory activities of IFN-gamma depend on constitutively expressed IL-1alpha. Proc Natl Acad Sci U S A. 2007; 104:5044–5049.
34. Pak-Wittel MA, Yang L, Sojka DK, Rivenbark JG, Yokoyama WM. Interferon-γ mediates chemokine-dependent recruitment of natural killer cells during viral infection. Proc Natl Acad Sci U S A. 2013; 110:E50–E59.
35. Takikawa O, Habara-Ohkubo A, Yoshida R. IFN-gamma is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection. J Immunol. 1990; 145:1246–1250.
36. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science. 1993; 261:1445–1448.
37. Kane M, Zang TM, Rihn SJ, Zhang F, Kueck T, Alim M, Schoggins J, Rice CM, Wilson SJ, Bieniasz PD. Identification of interferon-stimulated genes with antiretroviral activity. Cell Host Microbe. 2016; 20:392–405.
38. Harris N, Buller RM, Karupiah G. Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J Virol. 1995; 69:910–915.
39. Komatsu T, Bi Z, Reiss CS. Interferon-gamma induced type I nitric oxide synthase activity inhibits viral replication in neurons. J Neuroimmunol. 1996; 68:101–108.
40. Lin YL, Huang YL, Ma SH, Yeh CT, Chiou SY, Chen LK, Liao CL. Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication. J Virol. 1997; 71:5227–5235.
41. Guidotti LG, McClary H, Loudis JM, Chisari FV. Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J Exp Med. 2000; 191:1247–1252.
42. Terajima M, Leporati AM. Role of indoleamine 2,3-dioxygenase in antiviral activity of interferon-gamma against vaccinia virus. Viral Immunol. 2005; 18:722–729.
43. Jarasch N, Martin U, Kamphausen E, Zell R, Wutzler P, Henke A. Interferon-gamma-induced activation of nitric oxide-mediated antiviral activity of macrophages caused by a recombinant coxsackievirus B3. Viral Immunol. 2005; 18:355–364.
44. Becerra A, Warke RV, Xhaja K, Evans B, Evans J, Martin K, de Bosch N, Rothman AL, Bosch I. Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function. J Gen Virol. 2009; 90:810–817.
45. Mao R, Zhang J, Jiang D, Cai D, Levy JM, Cuconati A, Block TM, Guo JT, Guo H. Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol. 2011; 85:1048–1057.
46. Suri D, Schilling R, Lopes AR, Mullerova I, Colucci G, Williams R, Naoumov NV. Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J Hepatol. 2001; 35:790–797.
47. Patterson CE, Lawrence DM, Echols LA, Rall GF. Immune-mediated protection from measles virus-induced central nervous system disease is noncytolytic and gamma interferon dependent. J Virol. 2002; 76:4497–4506.
48. Burdeinick-Kerr R, Griffin DE. Gamma interferon-dependent, noncytolytic clearance of sindbis virus infection from neurons
in vitro
. J Virol. 2005; 79:5374–5385.
49. Zhang M, Daniel S, Huang Y, Chancey C, Huang Q, Lei YF, Grinev A, Mostowski H, Rios M, Dayton A. Anti-West Nile virus activity of
in vitro expanded human primary natural killer cells. BMC Immunol. 2010; 11:3.
50. Rodriguez M, Pavelko K, Coffman RL. Gamma interferon is critical for resistance to Theiler's virus-induced demyelination. J Virol. 1995; 69:7286–7290.
51. Selin LK, Varga SM, Wong IC, Welsh RM. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med. 1998; 188:1705–1715.
52. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001; 194:1395–1406.
53. Mudhakir D, Harashima H. Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. AAPS J. 2009; 11:65–77.
54. Mercer J, Schelhaas M, Helenius A. Virus entry by endocytosis. Annu Rev Biochem. 2010; 79:803–833.
55. Dhawan S, Heredia A, Wahl LM, Epstein JS, Meltzer MS, Hewlett IK. Interferon-gamma-induced downregulation of CD4 inhibits the entry of human immunodeficiency virus type-1 in primary monocytes. Pathobiology. 1995; 63:93–99.
56. Wei X, Jia ZS, Lian JQ, Zhang Y, Li J, Ma L, Ye L, Wang JP, Pan L, Wang PZ, et al. Inhibition of hepatitis C virus infection by interferon-gamma through downregulating claudin-1. J Interferon Cytokine Res. 2009; 29:171–178.
57. Douam F, Lavillette D, Cosset FL. The mechanism of HCV entry into host cells. Prog Mol Biol Transl Sci. 2015; 129:63–107.
58. Reynolds GM, Harris HJ, Jennings A, Hu K, Grove J, Lalor PF, Adams DH, Balfe P, Hübscher SG, McKeating JA. Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology. 2008; 47:418–427.
59. Rongcun Y, Maes H, Corsi M, Dellner F, Wen T, Kiessling R. Interferon gamma impairs the ability of monocyte-derived dendritic cells to present tumour-specific and allo-specific antigens and reduces their expression of CD1A, CD80 AND CD4. Cytokine. 1998; 10:747–755.
60. Day PM, Thompson CD, Lowy DR, Schiller JT. Interferon gamma prevents infectious entry of human papillomavirus 16 via an l2-dependent mechanism. J Virol. 2017; 91:pii: e00168-17.
61. Popa A, Zhang W, Harrison MS, Goodner K, Kazakov T, Goodwin EC, Lipovsky A, Burd CG, DiMaio D. Direct binding of retromer to human papillomavirus type 16 minor capsid protein L2 mediates endosome exit during viral infection. PLoS Pathog. 2015; 11:e1004699.
62. Kamiyama H, Kakoki K, Yoshii H, Iwao M, Igawa T, Sakai H, Hayashi H, Matsuyama T, Yamamoto N, Kubo Y. Infection of XC cells by MLVs and Ebola virus is endosome-dependent but acidification-independent. PLoS One. 2011; 6:e26180.
63. Kubo Y, Izumida M, Yashima Y, Yoshii-Kamiyama H, Tanaka Y, Yasui K, Hayashi H, Matsuyama T. Gamma-interferon-inducible, lysosome/endosome-localized thiolreductase, GILT, has anti-retroviral activity and its expression is counteracted by HIV-1. Oncotarget. 2016; 7:71255–71273.
64. Li D, Wei T, Abbott CM, Harrich D. The unexpected roles of eukaryotic translation elongation factors in RNA virus replication and pathogenesis. Microbiol Mol Biol Rev. 2013; 77:253–266.
65. Burdeinick-Kerr R, Govindarajan D, Griffin DE. Noncytolytic clearance of sindbis virus infection from neurons by gamma interferon is dependent on Jak/STAT signaling. J Virol. 2009; 83:3429–3435.
66. Rowland RR, Robinson B, Stefanick J, Kim TS, Guanghua L, Lawson SR, Benfield DA. Inhibition of porcine reproductive and respiratory syndrome virus by interferon-gamma and recovery of virus replication with 2-aminopurine. Arch Virol. 2001; 146:539–555.
67. García MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, Esteban M. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev. 2006; 70:1032–1060.
68. Grünvogel O, Esser-Nobis K, Reustle A, Schult P, Müller B, Metz P, Trippler M, Windisch MP, Frese M, Binder M, et al.
DDX60L is an interferon-stimulated gene product restricting hepatitis c virus replication in cell culture. J Virol. 2015; 89:10548–10568.
69. Windisch MP, Frese M, Kaul A, Trippler M, Lohmann V, Bartenschlager R. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J Virol. 2005; 79:13778–13793.
70. den Boon JA, Diaz A, Ahlquist P. Cytoplasmic viral replication complexes. Cell Host Microbe. 2010; 8:77–85.
71. Biering SB, Choi J, Halstrom RA, Brown HM, Beatty WL, Lee S, McCune BT, Dominici E, Williams LE, Orchard RC, et al. Viral replication complexes are targeted by lc3-guided interferon-inducible GTPases. Cell Host Microbe. 2017; 22:74–85.e7.
72. Abend JR, Low JA, Imperiale MJ. Inhibitory effect of gamma interferon on BK virus gene expression and replication. J Virol. 2007; 81:272–279.
73. Pierce AT, DeSalvo J, Foster TP, Kosinski A, Weller SK, Halford WP. Beta interferon and gamma interferon synergize to block viral DNA and virion synthesis in herpes simplex virus-infected cells. J Gen Virol. 2005; 86:2421–2432.
74. Choudhary S, Gao J, Leaman DW, De BP. Interferon action against human parainfluenza virus type 3: involvement of a novel antiviral pathway in the inhibition of transcription. J Virol. 2001; 75:4823–4831.
75. Rhein BA, Powers LS, Rogers K, Anantpadma M, Singh BK, Sakurai Y, Bair T, Miller-Hunt C, Sinn P, Davey RA, et al. Interferon-gamma inhibits ebola virus infection. PLoS Pathog. 2015; 11:e1005263.
76. Morikawa K, Suda G, Sakamoto N. Viral life cycle of hepatitis B virus: host factors and druggable targets. Hepatol Res. 2016; 46:871–877.
77. Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol. 2007; 13:48–64.
78. Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, Michler T, Wisskirchen K, Cheng X, Zhang K, et al. Interferon-gamma and tumor necrosis factor-alpha produced by t cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016; 150:194–205.
79. Kouwaki T, Fukushima Y, Daito T, Sanada T, Yamamoto N, Mifsud EJ, Leong CR, Tsukiyama-Kohara K, Kohara M, Matsumoto M, et al. Extracellular vesicles including exosomes regulate innate immune responses to hepatitis b virus infection. Front Immunol. 2016; 7:335.
80. Oshiumi H, Miyashita M, Okamoto M, Morioka Y, Okabe M, Matsumoto M, Seya T. DDX60 is involved in RIG-I-dependent and independent antiviral responses, and its function is attenuated by virus-induced EGFR activation. Cell Reports. 2015; 11:1193–1207.
81. Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, Wei L, Chang J, Block TM, Guo JT. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol. 2010; 84:9332–9340.
82. Robek MD, Wieland SF, Chisari FV. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol. 2002; 76:3570–3574.
83. Song R, Koyuncu OO, Greco TM, Diner BA, Cristea IM, Enquist LW. Two modes of the axonal interferon response limit alphaherpesvirus neuroinvasion. MBio. 2016; 7:e02145-15.
84. Mikloska Z, Cunningham AL. Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmission. J Virol. 2001; 75:11821–11826.
85. Rihn SJ, Foster TL, Busnadiego I, Aziz MA, Hughes J, Neil SJ, Wilson SJ. The envelope gene of transmitted HIV-1 resists a late interferon gamma-induced block. J Virol. 2017; 91:pii: e02254-16.
86. Lahiri Mukhopadhyay S, Bahubali VH, Manjunath N, Swaminathan A, Maji S, Palaniappan M, Parthasarathy S, Chandrashekar N. Central nervous system infection due to
Cryptococcus gattii sensu lato in India: analysis of clinical features, molecular profile and antifungal susceptibility. Mycoses. 2017; 60:749–757.
87. Mikloska Z, Sanna PP, Cunningham AL. Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells
in vitro
. J Virol. 1999; 73:5934–5944.
88. Traylen CM, Patel HR, Fondaw W, Mahatme S, Williams JF, Walker LR, Dyson OF, Arce S, Akula SM. Virus reactivation: a panoramic view in human infections. Future Virol. 2011; 6:451–463.
89. Pozharskaya VP, Weakland LL, Offermann MK. Inhibition of infectious human herpesvirus 8 production by gamma interferon and alpha interferon in BCBL-1 cells. J Gen Virol. 2004; 85:2779–2787.
90. Steed A, Buch T, Waisman A, Virgin HW 4th. Gamma interferon blocks gammaherpesvirus reactivation from latency in a cell type-specific manner. J Virol. 2007; 81:6134–6140.
91. Steed AL, Barton ES, Tibbetts SA, Popkin DL, Lutzke ML, Rochford R, Virgin HW 4th. Gamma interferon blocks gammaherpesvirus reactivation from latency. J Virol. 2006; 80:192–200.
92. Milligan S, Robinson M, O'Donnell E, Blackbourn DJ. Inflammatory cytokines inhibit Kaposi's sarcoma-associated herpesvirus lytic gene transcription in
in vitro-infected endothelial cells. J Virol. 2004; 78:2591–2596.
93. Decman V, Kinchington PR, Harvey SA, Hendricks RL. Gamma interferon can block herpes simplex virus type 1 reactivation from latency, even in the presence of late gene expression. J Virol. 2005; 79:10339–10347.
94. Liu T, Khanna KM, Carriere BN, Hendricks RL. Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J Virol. 2001; 75:11178–11184.
95. De-Simone FI, Sariyer R, Otalora YL, Yarandi S, Craigie M, Gordon J, Sariyer IK. IFN-gamma inhibits JC virus replication in glial cells by suppressing t-antigen expression. PLoS One. 2015; 10:e0129694.
96. Choi J, Park S, Biering SB, Selleck E, Liu CY, Zhang X, Fujita N, Saitoh T, Akira S, Yoshimori T, et al. The parasitophorous vacuole membrane of
Toxoplasma gondii is targeted for disruption by ubiquitin-like conjugation systems of autophagy. Immunity. 2014; 40:924–935.
97. Park S, Choi J, Biering SB, Dominici E, Williams LE, Hwang S. Targeting by AutophaGy proteins (TAG): targeting of IFNG-inducible GTPases to membranes by the LC3 conjugation system of autophagy. Autophagy. 2016; 12:1153–1167.
98. Choi J, Biering SB, Hwang S. Quo vadis? Interferon-inducible GTPases go to their target membranes via the lc3-conjugation system of autophagy. Small GTPases. 2017; 8:199–207.
99. Biering SB, Choi J, Brown HM, Hwang S. LC3s hire membrane breakers to attack viral shelters. Autophagy. 2017; 13:2010–2012.
100. Brown HM, Biering SB, Zhu A, Choi J, Hwang S. Demarcation of viral shelters results in destruction by membranolytic GTPases: antiviral function of autophagy proteins and interferon-inducible GTPases. BioEssays. 2018; 40:e1700231.
101. Ng CT, Mendoza JL, Garcia KC, Oldstone MB. Alpha and beta type 1 interferon signaling: passage for diverse biologic outcomes. Cell. 2016; 164:349–352.
102. Kim BH, Chee JD, Bradfield CJ, Park ES, Kumar P, MacMicking JD. Interferon-induced guanylate-binding proteins in inflammasome activation and host defense. Nat Immunol. 2016; 17:481–489.
103. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015; 15:405–414.
104. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015; 15:87–103.